Mylan N.V. has announced the US launches of the generic versions of two antihypertensive drugs by Daiichi Sankyo, Benicar and Benicar HCT, olmesartan medoxomil tablets, 5 mg, 20 mg and 40 mg, and olmesartan medoxomil and hydrochlorothiazide tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg, respectively. Mylan received final approval from the US Food and Drug Administration for its abbreviated new drug applications for these products.

Olmesartan medoxomil tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are indicted for the treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension.

Olmesartan medoxomil tablets, 5 mg, 20 mg and 40 mg, had US sales of approximately $1 billion for the 12 months ending August 31, 2016, according to IMS Health, and as reported by Mylyan. Olmesartan medoxomil and hydrochlorothiazide tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg had US sales of approximately $805 million during that same time.

Source: Mylan